Press Releases

BERLIN, GERMANY--(Marketwire - Sept. 5, 2008) - Bombardier Transportation has received an order from the Danish State Railways (DSB) for the delivery of 10 three-car Contessa trains, valued at approximately 82 million euros ($118 million US), with a foreseeable option of 30 additional trains.

The trains, which can reach a maximum speed of 180 km/h, are capable of crossing the bridge between Denmark and Sweden despite the different rail infrastructures used in both countries. The trains automatically shift signalling and power systems when crossing the border thanks to a sophisticated dual system integrated into the vehicles. Other features of the inter-regional train include a middle-car design with low floors, and entrances giving access to disabled passengers and passengers carrying heavy luggage, for example.

Since the start of operation in July 2000, the Contessa trains, crossing the bridge between Sweden and Denmark, have become a vital part of the everyday life for thousands of commuters and are one of the key factors behind the successful integration of the prosperous Oresund region. It also links the entire southern part of Sweden to Denmark and the rest of Europe.

"I am very happy that our subsidiary, DSBFirst, will now be able to offer our many daily customers an even better service with the purchase of more Oresund trains. Previously, we have been the victims of our own success, so to speak. The massive growth in passenger numbers across the Oresund has occasionally led to an insufficient number of seats during peak hour. Consequently, some of our customers have had to remain standing on their way to or from work. With these additional 10 train sets, we aim to increase the satisfaction of our customers in the future", said DSB's Chief Executive Officer, Soren Eriksen.

The trains will be leased by the National Rail Authority, which will, in turn, make the trains available for DSBFirst, when the company takes over the Oresund services as of 11 January 2009.

Commenting on the order, President of Bombardier's Passenger Division, Stephane Rambaud-Measson, said: "This new order confirms our commitment to continously evolving and improving our Contessa trains. Comfort and flexibility are just some of the features to be enjoyed by this highly reliable product. We are proud that DSB once again opted for this product in order to enhance its service quality. 79 Contessa trains are already in successful operation in Denmark and Sweden."

The vehicles and propulsion equipment will be designed by Bombardier in Sweden, with the propulsion equipment being manufactured at Bombardier's production site in Vasteras. The cars will be produced in Germany at Bombardier's Hennigsdorf and Gorlitz production sites, while the bogies will be produced in Siegen.

Note to Editors:

A photo is available on our web site at: http://www.transportation.bombardier.com

About Bombardier Transportation

Bombardier Transportation has its global headquarters in Berlin, Germany with a presence in over 60 countries. It has an installed base of over 100,000 vehicles worldwide. The Group offers the broadest product portfolio and is recognized as the leader in the global rail sector.

About Bombardier

A world-leading manufacturer of innovative transportation solutions, from commercial aircraft and business jets to rail transportation equipment, systems and services, Bombardier Inc. is a global corporation headquartered in Canada. Its revenues for the fiscal year ended Jan. 31, 2008, were $17.5 billion US, and its shares are traded on the Toronto Stock Exchange (BBD). Bombardier is listed as an index component to the Dow Jones Sustainability World and North America indexes. News and information are available at www.bombardier.com.

www.theclimateisrightfortrains.com

FOR FURTHER INFORMATION PLEASE CONTACT:
        Americas
        David Slack
        + 1 450 441 3190
        david.slack@ca.transport.bombardier.com

        Germany, Austria, Central and Eastern Europe
        Heiner Spannuth
        +49 30 986 07 1134
        heiner.spannuth@de.transport.bombardier.com

        Switzerland
        Fiona Flannery
        +41 44 318 29 91
        fiona.flannery@ch.transport.bombardier.com

        Nordic Countries
        Jonny Hedberg
        +46 8 681 5062
        jonny.hedberg@se.transport.bombardier.com

        Russia
        Alexander Bocharov
        +7 495 775 1830
        alexander.bocharov@ru.transport.bombardier.com

        UK, Ireland, Australia, New Zealand, other countries
        Neil Harvey
        +44 1332 266470
        neil.harvey@uk.transport.bombardier.com

        Benelux
        Guy Hendrix
        +32 2289 7341
        guy.hendrix@be.transport.bombardier.com

        France
        Anne Froger
        +33 6 07 78 95 38
        anne.froger@fr.transport.bombardier.com

Source: Bombardier Transportation

HOUSTON, TEXAS--(Marketwire - Sept. 5, 2008) - Caza (TSX: CAZ)(AIM: CAZA) is pleased to provide an operational update on the Company's activities in Upton, Duval and Wharton Counties, Texas.

Glass Ranch Property - Upton County, Texas, the Glass Ranch B #3 well has successfully encountered hydrocarbons. The well, operated by Momentum Energy Corporation of Midland, Texas, reached a total depth of 10,426 feet on August 21, 2008. Electric logs indicated multiple potential pay sands in the Wolfcamp and Spraberry formations. Completion operations have commenced and fracture stimulation is planned for the near future. Following the success, the rig is being moved to an offsetting location to spud the Glass Ranch A #3 well.

Caza currently has a 50.0% working interest and a corresponding 38.54% net revenue interest before payout of the well, which will change after payout to an estimated 47.41% working interest and an estimated 35.78% net revenue interest.

Rosita Creek Property - Duval County, Texas, the Perez No. 1 well reached its target depth of 3,616 feet in the Jackson Bar Sands formation on August 27, 2008. The well was logged but did not encounter hydrocarbons. The capital outlay for this shallow test was not material, and the information from the Perez No. 1 well will help to further evaluate the shallow drilling potential of this area.

Caza is the operator of this well and has a 65.0% working interest and a corresponding 52.0% net revenue interest.

Wilcox 116 Property - Wharton County, Texas, the Jonell Cerny Gas Unit #1 well, as previously announced on August 4, 2008, was completed in the Yegua formation and had been awaiting fracture stimulation. The well was fracture stimulated on August 25, 2008. Initial gross rates are approximately 40 barrels of oil per day from perforated intervals between 10,966 and 10,991 feet. Caza is evaluating further opportunities to access additional Yegua intervals.

Caza is the operator of this well and has a 27.8% working interest and a corresponding 20.9% net revenue interest.

John McGoldrick, Executive Chairman of the Company, commented:

"The Glass Ranch B #3 is the third of four planned wells on our Glass Ranch property. In the event of success on both the Glass Ranch A #3 well and the planned stimulation procedures on all four Glass Ranch wells, we may opt to drill two additional wells on this property in the near future. We are very pleased with the results of the program thus far, and given continued success anticipate expanding our lease position throughout this trend."

About Caza

Caza is engaged in the acquisition, exploration, development and production of hydrocarbons in the Texas Gulf Coast (on-shore), south Louisiana, southeast New Mexico and the Permian Basin of west Texas regions of the United States of America through its subsidiary, Caza Petroleum, Inc.

In accordance with AIM Rules - Guidance Note for Mining, Oil and Gas Companies, the information contained in this announcement has been reviewed and approved by Anthony B. Sam, Vice President Operations of Caza who is a Petroleum Engineer and a member of The Society of Petroleum Engineers.

ADVISORY REGARDING FORWARD-LOOKING STATEMENTS - In the interests of providing Caza shareholders and potential investors with information regarding Caza, including management's assessment of Caza's and its subsidiaries' future plans and operations, certain statements contained in this news release are forward-looking statements or information within the meaning of applicable securities legislation, collectively referred to herein as "forward-looking statements". Forward-looking statements in this news release include, but are not limited to: future economic and operating performance (including per share growth, cash flow and increase in net asset value); anticipated growth and success of resource plays and the expected characteristics of resource plays; free cash flow which may be generated in 2008 and beyond, and potential uses for such free cash flow; anticipated production and sales of oil, natural gas and NGLs in 2008; anticipated impact and success of Caza's price hedging strategy, if any; anticipated costs; anticipated prices for oil and natural gas; anticipated capital investment in 2008 and the allocation thereof; anticipated capital inflation; anticipated capital and operating cost efficiencies; anticipated growth in hydrocarbon production; forecast cash flow for 2008 and the anticipated ability to meet guidance targets. Statements regarding flow rates in this news release are current only as of the date hereof. Future flow rates may vary, perhaps materially, and the wells in question may prove to be technically or economically unviable. Any future flow rates will be subject to the risks and uncertainties set out in this news release.

Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause the company's actual performance and financial results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These risks and uncertainties include, among other things: volatility of and assumptions regarding oil and gas prices; assumptions based upon the company's current guidance; fluctuations in currency exchange and interest rates; product supply and demand; market competition; well flow rates and the hydrocarbons ultimately recoverable from wells, operating risks, water encroachment, risks inherent in the company's marketing operations, including credit risks; imprecision of reserve estimates and estimates of recoverable quantities of oil, natural gas and liquids from resource plays and other sources not currently classified as proved; the company's ability to replace and expand oil and gas reserves; the company's ability to generate sufficient cash flow from operations to meet its current and future obligations; the company's ability to access external sources of debt and equity capital; the timing and the costs of well and pipeline construction; the company's ability to secure adequate product transportation; changes in royalty, tax, environmental and other laws or regulations or the interpretations of such laws or regulations; the risk of terrorist threats; risks associated with future lawsuits and regulatory actions made against the company; and other risks and uncertainties described from time to time in the reports and filings made with securities regulatory authorities by Caza.

Although Caza believes that the expectations represented by such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned that the foregoing list of important factors is not exhaustive. Furthermore, the forward-looking statements contained in this news release are made as of the date of this news release, and, except as required by law or regulation, Caza does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

The Toronto Stock Exchange has neither approved nor disapproved the information contained herein.

FOR FURTHER INFORMATION PLEASE CONTACT:
        Caza Oil & Gas, Inc.
        John McGoldrick
        Executive Chairman
        (281) 363-4442
        Website: www.cazapetro.com

        Noble & Company Limited
        Nick Naylor / Jamie Boyd
        Nominated Adviser and Joint Broker
        +44 (0) 20 7763 2200

        Aquila Financial Ltd.
        Peter Reilly
        Financial Public Relations Advisers
        +44 (0) 118 979 4100

Source: Caza Oil & Gas, Inc.

TAMPA, Fla.--(BUSINESS WIRE)--

UTEK Corporation (AMEX: UTK) (LSE-AIM: UTK), an innovation services company, announced today that Clifford M. Gross, Ph.D., Chief Executive Officer, is scheduled to deliver a corporate presentation at the Merriman Curhan Ford Investor Summit at the Mark Hopkins Hotel in San Francisco, CA.

The UTEK Corporation presentation is scheduled for Monday, September 15th at 9:00 am PT.

About UTEK Corporation

UTEK(R) is a leading innovation services company. UTEK's services enable clients to become stronger innovators, rapidly source externally developed technologies and create value from their intellectual property. UTEK is a business development company with operations in the United States and the United Kingdom. For more information about UTEK, please visit its website at www.utekcorp.com.

Forward-Looking Statements

Certain matters discussed in this press release are "forward-looking statements." These forward-looking statements can generally be identified as such because the context of the statement will include words, such as UTEK "expects," "should," "believes," "anticipates" or words of similar import. Similarly, statements that describe UTEK's future plans, objectives or goals are also forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties, including the financial performance of UTEK, and the valuation of UTEK's investment portfolio, which could cause actual results to differ materially from those currently anticipated. Although UTEK believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, it cannot give any assurance that its expectations will be attained. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating any forward-looking statements. Certain factors could cause results and conditions to differ materially from those projected in these forward-looking statements, and some of these factors are discussed below. These factors are not exhaustive. New factors, risks and uncertainties may emerge from time to time that may affect the forward-looking statements made herein. These forward-looking statements are only made as of the date of this press release and UTEK does not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

UTEK's operating results could fluctuate significantly due to a number of factors. These factors include the small number of transactions that are completed each quarter, the value of individual transactions, the timing of the recognition and the magnitude of unrealized and realized gains and losses of companies in its portfolio, UTEK's dependence on the performance of companies in its portfolio, the possibility that advances in technology could render the technologies it has transferred obsolete, the loss of technology licenses by companies in its portfolio, the degree to which it encounters competition in its markets, the volatility of the stock market and the volatility of the valuations of the companies it has invested in as it relates to its realized and unrealized gains and losses, the concentration of investments in a small number of companies, as well as other general economic conditions. As a result of these and other factors, current results may not be indicative of UTEK's future performance. For more information on UTEK and for a more complete discussion of the risks pertaining to an investment in UTEK, please refer to UTEK's filings with the Securities and Exchange Commission.

Source: UTEK Corporation

CAMBRIDGE, Mass. & DUBLIN, Ireland--(BUSINESS WIRE)--

Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) today announced the initiation of the first clinical trial of TYSABRI(R) (natalizumab) in oncology. The first dose of TYSABRI was administered yesterday in the trial. The objectives of this Phase I/II study are to evaluate the safety and potential anti-tumor activity of TYSABRI in patients with relapsed or refractory multiple myeloma. TYSABRI is a recombinant, humanized monoclonal antibody that targets the adhesion molecule VLA4 (also known as alpha-4 integrin) that is expressed on the surface of many types of immune cells. VLA4 is also found on the surface of multiple myeloma cells and may be involved in their survival.

"We are excited to initiate the oncology clinical trial program for TYSABRI," said Wayne Saville, MD, Director, Oncology Medical Research at Biogen Idec. "TYSABRI has potential in multiple myeloma and a number of other cancers through its action as a blocker of VLA4. It is a meaningful addition to Biogen Idec's robust oncology pipeline."

"This clinical trial in oncology represents an opportunity for TYSABRI to continue to address unmet medical needs, potentially bringing new therapeutic options to patients and their oncologists," said Gordon Francis, MD, Senior Vice President, Global Clinical Development at Elan Pharmaceuticals, Inc.

About the Trial

This Phase I/II, open-label, two-arm study is designed to evaluate the safety and anti-tumor activity of TYSABRI in patients with relapsed or refractory multiple myeloma. In the Phase I portion of the trial, a standard dose-escalation design will be used to assess the safety and tolerability of TYSABRI in up to 12 patients. In the Phase II portion of the study, up to 30 patients will be randomized to the tolerated doses identified in Phase I of the study.

Treatment cycles will consist of intravenous infusions of TYSABRI once every 28 days for 6 months. After 6 months, if the patient has achieved a partial or a complete response, he or she may continue to receive TYSABRI once every 28 days until progression of disease occurs.

Patients eligible for the study must be at least 18 years of age with relapsed or refractory multiple myeloma who have failed or cannot tolerate therapy with bortezomib and thalidomide or lenalidomide.

About Multiple Myeloma

Multiple myeloma is a cancer of the plasma cell, an important part of the immune system that produces antibodies to help fight infection and disease. Certain immune cells, called B cells, change into plasma cells when they respond to an antigen, producing antibodies to attack bacteria and viruses. However, when plasma cells multiply in an uncontrolled way, they can produce tumors, which generally develop in the bone marrow. These plasma cells produce excessive amounts of antibodies and can interfere with normal blood-forming functions of the bone marrow, crowding out healthy cells and leaving patients susceptible to anemia, hemorrhage, infection and severe osteoporosis.

Multiple myeloma is the second most common blood cancer in the United States (US). More than 50,000 people in the US are living with multiple myeloma, and about 20,000 new cases are expected to be diagnosed this year. Nearly 11,000 Americans are expected to die from the disease this year. Men are 50 percent more likely to develop the disease than women. Other risk factors include race, radiation exposure, family history, occupational exposure to petroleum, obesity and other plasma cell disorders.

About TYSABRI

TYSABRI is a treatment approved for relapsing forms of MS in the United States and relapsing-remitting MS in the European Union. According to data that have been published in the New England Journal of Medicine, after two years, TYSABRI treatment led to a 68% relative reduction (p<0.001) in the annualized relapse rate compared to placebo and reduced the relative risk of disability progression by 42-54% (p<0.001).

TYSABRI was recently approved to induce and maintain clinical response and remission in adult patients with moderately to severely active Crohn's disease (CD) with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-alpha.

TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability. Cases of PML have been reported in patients taking TYSABRI who were recently or concomitantly treated with immunomodulators or immunosuppressants, as well as in patients receiving TYSABRI as monotherapy. Other serious adverse events that have occurred in TYSABRI-treated patients included hypersensitivity reactions (e.g., anaphylaxis) and infections. Serious opportunistic and other atypical infections have been observed in TYSABRI-treated patients, some of whom were receiving concurrent immunosuppressants. Herpes infections were slightly more common in patients treated with TYSABRI. In MS and CD clinical trials, the incidence and rate of other serious adverse events, including serious infections, were similar in patients receiving TYSABRI and those receiving placebo. Common adverse events reported in TYSABRI-treated MS patients include headache, fatigue, infusion reactions, urinary tract infections, joint and limb pain and rash. Other common adverse events reported in TYSABRI-treated CD patients include respiratory tract infections and nausea. Clinically significant liver injury has been reported in patients treated with TYSABRI in the post-marketing setting.

TYSABRI is approved in more than 35 countries.

For more information about TYSABRI please visit www.tysabri.com, www.biogenidec.com or www.elan.com or call 1-800-456-2255.

About Elan

Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York, London and Dublin Stock Exchanges. For additional information about the company, please visit www.elan.com.

About Biogen Idec

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.

Safe Harbor/Forward-Looking Statements

This press release contains forward-looking statements regarding the potential use of TYSABRI. These statements are based on the companies' current beliefs and expectations. The development of TYSABRI in new indications and its commercial potential are subject to a number of risks and uncertainties. Factors which could cause actual results to differ materially from the companies' current expectations include but are not limited to the risk that we may be unable to adequately address concerns or questions raised by FDA or other regulatory authorities, that concerns may arise from additional data, that the incidence and/or risk of PML or other opportunistic infections in patients treated with TYSABRI may be higher than observed in clinical trials, or that the companies may encounter other unexpected hurdles. Drug development and commercialization involves a high degree of risk.

For more detailed information on the risks and uncertainties associated with the companies' drug development and other activities, see the periodic and current reports that Biogen Idec and Elan have filed with the Securities and Exchange Commission. The companies assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Source: Biogen Idec and Elan Corporation, plc

BERLIN, GERMANY -- (MARKET WIRE) -- 09/05/08 -- Bombardier Transportation has received an order from the Danish State Railways (DSB) for the delivery of 10 three-car Contessa trains, valued at approximately 82 million euros ($118 million US), with a foreseeable option of 30 additional trains.

The trains, which can reach a maximum speed of 180 km/h, are capable of crossing the bridge between Denmark and Sweden despite the different rail infrastructures used in both countries. The trains automatically shift signalling and power systems when crossing the border thanks to a sophisticated dual system integrated into the vehicles. Other features of the inter-regional train include a middle-car design with low floors, and entrances giving access to disabled passengers and passengers carrying heavy luggage, for example.

Since the start of operation in July 2000, the Contessa trains, crossing the bridge between Sweden and Denmark, have become a vital part of the everyday life for thousands of commuters and are one of the key factors behind the successful integration of the prosperous Oresund region. It also links the entire southern part of Sweden to Denmark and the rest of Europe.

"I am very happy that our subsidiary, DSBFirst, will now be able to offer our many daily customers an even better service with the purchase of more Oresund trains. Previously, we have been the victims of our own success, so to speak. The massive growth in passenger numbers across the Oresund has occasionally led to an insufficient number of seats during peak hour. Consequently, some of our customers have had to remain standing on their way to or from work. With these additional 10 train sets, we aim to increase the satisfaction of our customers in the future", said DSB's Chief Executive Officer, Soren Eriksen.

The trains will be leased by the National Rail Authority, which will, in turn, make the trains available for DSBFirst, when the company takes over the Oresund services as of 11 January 2009.

Commenting on the order, President of Bombardier's Passenger Division, Stephane Rambaud-Measson, said: "This new order confirms our commitment to continously evolving and improving our Contessa trains. Comfort and flexibility are just some of the features to be enjoyed by this highly reliable product. We are proud that DSB once again opted for this product in order to enhance its service quality. 79 Contessa trains are already in successful operation in Denmark and Sweden."

The vehicles and propulsion equipment will be designed by Bombardier in Sweden, with the propulsion equipment being manufactured at Bombardier's production site in Vasteras. The cars will be produced in Germany at Bombardier's Hennigsdorf and Gorlitz production sites, while the bogies will be produced in Siegen.

Note to Editors:

A photo is available on our web site at: http://www.transportation.bombardier.com

About Bombardier Transportation

Bombardier Transportation has its global headquarters in Berlin, Germany with a presence in over 60 countries. It has an installed base of over 100,000 vehicles worldwide. The Group offers the broadest product portfolio and is recognized as the leader in the global rail sector.

About Bombardier

A world-leading manufacturer of innovative transportation solutions, from commercial aircraft and business jets to rail transportation equipment, systems and services, Bombardier Inc. is a global corporation headquartered in Canada. Its revenues for the fiscal year ended Jan. 31, 2008, were $17.5 billion US, and its shares are traded on the Toronto Stock Exchange (BBD). Bombardier is listed as an index component to the Dow Jones Sustainability World and North America indexes. News and information are available at www.bombardier.com.

www.theclimateisrightfortrains.com

Contacts:
Americas
David Slack
+ 1 450 441 3190
david.slack@ca.transport.bombardier.com

Germany, Austria, Central and Eastern Europe
Heiner Spannuth
+49 30 986 07 1134
heiner.spannuth@de.transport.bombardier.com

Switzerland
Fiona Flannery
+41 44 318 29 91
fiona.flannery@ch.transport.bombardier.com

Nordic Countries
Jonny Hedberg
+46 8 681 5062
jonny.hedberg@se.transport.bombardier.com

Russia
Alexander Bocharov
+7 495 775 1830
alexander.bocharov@ru.transport.bombardier.com

UK, Ireland, Australia, New Zealand, other countries
Neil Harvey
+44 1332 266470
neil.harvey@uk.transport.bombardier.com

Benelux
Guy Hendrix
+32 2289 7341
guy.hendrix@be.transport.bombardier.com

France
Anne Froger
+33 6 07 78 95 38
anne.froger@fr.transport.bombardier.com